Woodford Debacle Is A Test Of UK Biotech’s Resilience
Investor's Downfall Is Unwelcome Distraction
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
You may also be interested in...
BenevolentAI Goes Public In Europe’s Largest SPAC
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
Interview: Why Europe’s Biotech ‘Prime Time’ Is Now
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
BioNTech Falls Short In Jittery IPO Market
After ADC Therapeutics